The study, which was published in the academic journal, the European Respiratory Journal , was led by Sarah Brode, PhD, assistant professor of medicine at the University of Toronto, Canada. Using existing data collected on 417,494 people aged 66 and older in Ontario, Canada, Dr. Brode’s team discovered that people who had been prescribed inhaled corticosteroids for the treatment of either asthma or COPD experienced 2,966 cases of nontuberculous myocobacteria (NTB). The association was particularly strong in patients who were using the corticosteroid fluticasone , an ingredient in the allergy medication, Flonase . The risk seemed to be lower for patients using the corticosteroid, budesonide .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of AirDuo™ RespiClick® and its Authorized Generic, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
While propylhexedrine is limited in a number of administration routes, attempts to extract the drug from the nasal inhaler and then inject it have been reported. Recreational use by intravenous injection (IV) is dangerous and could result in serious bodily harm or death. IV use of propylhexedrine is known to cause mild side-effects such as transient diplopia as well as some serious (and potentially fatal) effects such as brainstem dysfunction, and deaths have been recorded in the medical literature. Typically, recorded cases of IV use are prepared by forming propylhexedrine HCl in a solution with hydrochloric acid, the solution is then heated to evaporate and the resulting crystals are dissolved in water for injection.